GENINCODE PLC LS -01 - Asset Resilience Ratio
GENINCODE PLC LS -01 (9PL) has an Asset Resilience Ratio of 1.54% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how GENINCODE PLC LS -01's Asset Resilience Ratio has changed over time. See financial agility of GENINCODE PLC LS -01 to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down GENINCODE PLC LS -01's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of GENINCODE PLC LS -01.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €65.00K | 1.54% |
| Total Liquid Assets | €65.00K | 1.54% |
Asset Resilience Insights
- Limited Liquidity: GENINCODE PLC LS -01 maintains only 1.54% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
GENINCODE PLC LS -01 Industry Peers by Asset Resilience Ratio
Compare GENINCODE PLC LS -01's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Prodia Widyahusada Tbk PT
JK:PRDA |
Diagnostics & Research | 7.82% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
Annual Asset Resilience Ratio for GENINCODE PLC LS -01 (2021–2024)
The table below shows the annual Asset Resilience Ratio data for GENINCODE PLC LS -01.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.07% | €55.00K ≈ $64.30K |
€2.66 Million ≈ $3.11 Million |
+1.06pp |
| 2023-12-31 | 1.00% | €42.00K ≈ $49.10K |
€4.19 Million ≈ $4.89 Million |
+0.87pp |
| 2022-12-31 | 0.14% | €16.00K ≈ $18.71K |
€11.80 Million ≈ $13.79 Million |
+0.11pp |
| 2021-12-31 | 0.03% | €4.00K ≈ $4.68K |
€15.21 Million ≈ $17.78 Million |
-- |
About GENINCODE PLC LS -01
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to prov… Read more